Cognitive assessment in Huntington disease clinical drug trials

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

Several Huntington disease (HD) clinical trials are in progress and on the horizon. Potential treatments are increasingly being targeted at ameliorating the cognitive decline in HD. This necessitates a careful consideration of trial designs, including endpoint strategies suitable for testing cognitive function. The aim of this chapter is to evaluate and consider the use of cognitive measures in HD clinical trials. We first consider the role of cognition in clinical trial endpoint models, including a review of previous HD clinical trials that have included cognitive measures. We evaluate strategies for selecting cognitive tools for HD clinical trials, and consider cognitive assessments that have been used in other neuropsychiatric disorders, namely Alzheimer disease and schizophrenia. Next, we describe a general framework for selecting patient-based outcomes in clinical trials, and apply this framework to the selection of cognitive outcomes. Using the HD-Cognitive Assessment Battery (HD-CAB), a new cognitive battery designed for clinical trials, we illustrate the evaluation of cognitive outcomes in terms of their responsivity, reliability, validity, appropriateness, precision, interpretability, feasibility, and acceptability. Finally, we articulate a pathway for continued development of cognitive tools that would pave the way for finding treatments that ameliorate cognitive decline in HD.

Original languageEnglish
Title of host publicationHandbook of Clinical Neurology
EditorsAndrew S. Feigin, Karen E. Anderson
Place of PublicationNetherlands
PublisherElsevier
Chapter19
Pages227-244
Number of pages18
Volume144
ISBN (Electronic)9780128018934
DOIs
Publication statusPublished - 2017

Publication series

NameHandbook of Clinical Neurology
Volume144
ISSN (Print)0072-9752
ISSN (Electronic)2212-4152

Keywords

  • appropriateness
  • cognitive impairment
  • endpoint models
  • HD-CAB
  • interpretability
  • precision
  • psychometrics
  • reliability
  • responsivity
  • validity

Cite this

Stout, J. C., Andrews, S. C., & Glikmann-Johnston, Y. (2017). Cognitive assessment in Huntington disease clinical drug trials. In A. S. Feigin, & K. E. Anderson (Eds.), Handbook of Clinical Neurology (Vol. 144, pp. 227-244). (Handbook of Clinical Neurology; Vol. 144). Netherlands: Elsevier. https://doi.org/10.1016/B978-0-12-801893-4.00019-5
Stout, Julie C. ; Andrews, Sophie C. ; Glikmann-Johnston, Yifat. / Cognitive assessment in Huntington disease clinical drug trials. Handbook of Clinical Neurology. editor / Andrew S. Feigin ; Karen E. Anderson. Vol. 144 Netherlands : Elsevier, 2017. pp. 227-244 (Handbook of Clinical Neurology).
@inbook{3ed8894066bd464bad7f1a9a1bf94198,
title = "Cognitive assessment in Huntington disease clinical drug trials",
abstract = "Several Huntington disease (HD) clinical trials are in progress and on the horizon. Potential treatments are increasingly being targeted at ameliorating the cognitive decline in HD. This necessitates a careful consideration of trial designs, including endpoint strategies suitable for testing cognitive function. The aim of this chapter is to evaluate and consider the use of cognitive measures in HD clinical trials. We first consider the role of cognition in clinical trial endpoint models, including a review of previous HD clinical trials that have included cognitive measures. We evaluate strategies for selecting cognitive tools for HD clinical trials, and consider cognitive assessments that have been used in other neuropsychiatric disorders, namely Alzheimer disease and schizophrenia. Next, we describe a general framework for selecting patient-based outcomes in clinical trials, and apply this framework to the selection of cognitive outcomes. Using the HD-Cognitive Assessment Battery (HD-CAB), a new cognitive battery designed for clinical trials, we illustrate the evaluation of cognitive outcomes in terms of their responsivity, reliability, validity, appropriateness, precision, interpretability, feasibility, and acceptability. Finally, we articulate a pathway for continued development of cognitive tools that would pave the way for finding treatments that ameliorate cognitive decline in HD.",
keywords = "appropriateness, cognitive impairment, endpoint models, HD-CAB, interpretability, precision, psychometrics, reliability, responsivity, validity",
author = "Stout, {Julie C.} and Andrews, {Sophie C.} and Yifat Glikmann-Johnston",
year = "2017",
doi = "10.1016/B978-0-12-801893-4.00019-5",
language = "English",
volume = "144",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "227--244",
editor = "Feigin, {Andrew S.} and Anderson, {Karen E.}",
booktitle = "Handbook of Clinical Neurology",
address = "Netherlands",

}

Stout, JC, Andrews, SC & Glikmann-Johnston, Y 2017, Cognitive assessment in Huntington disease clinical drug trials. in AS Feigin & KE Anderson (eds), Handbook of Clinical Neurology. vol. 144, Handbook of Clinical Neurology, vol. 144, Elsevier, Netherlands, pp. 227-244. https://doi.org/10.1016/B978-0-12-801893-4.00019-5

Cognitive assessment in Huntington disease clinical drug trials. / Stout, Julie C.; Andrews, Sophie C.; Glikmann-Johnston, Yifat.

Handbook of Clinical Neurology. ed. / Andrew S. Feigin; Karen E. Anderson. Vol. 144 Netherlands : Elsevier, 2017. p. 227-244 (Handbook of Clinical Neurology; Vol. 144).

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Cognitive assessment in Huntington disease clinical drug trials

AU - Stout, Julie C.

AU - Andrews, Sophie C.

AU - Glikmann-Johnston, Yifat

PY - 2017

Y1 - 2017

N2 - Several Huntington disease (HD) clinical trials are in progress and on the horizon. Potential treatments are increasingly being targeted at ameliorating the cognitive decline in HD. This necessitates a careful consideration of trial designs, including endpoint strategies suitable for testing cognitive function. The aim of this chapter is to evaluate and consider the use of cognitive measures in HD clinical trials. We first consider the role of cognition in clinical trial endpoint models, including a review of previous HD clinical trials that have included cognitive measures. We evaluate strategies for selecting cognitive tools for HD clinical trials, and consider cognitive assessments that have been used in other neuropsychiatric disorders, namely Alzheimer disease and schizophrenia. Next, we describe a general framework for selecting patient-based outcomes in clinical trials, and apply this framework to the selection of cognitive outcomes. Using the HD-Cognitive Assessment Battery (HD-CAB), a new cognitive battery designed for clinical trials, we illustrate the evaluation of cognitive outcomes in terms of their responsivity, reliability, validity, appropriateness, precision, interpretability, feasibility, and acceptability. Finally, we articulate a pathway for continued development of cognitive tools that would pave the way for finding treatments that ameliorate cognitive decline in HD.

AB - Several Huntington disease (HD) clinical trials are in progress and on the horizon. Potential treatments are increasingly being targeted at ameliorating the cognitive decline in HD. This necessitates a careful consideration of trial designs, including endpoint strategies suitable for testing cognitive function. The aim of this chapter is to evaluate and consider the use of cognitive measures in HD clinical trials. We first consider the role of cognition in clinical trial endpoint models, including a review of previous HD clinical trials that have included cognitive measures. We evaluate strategies for selecting cognitive tools for HD clinical trials, and consider cognitive assessments that have been used in other neuropsychiatric disorders, namely Alzheimer disease and schizophrenia. Next, we describe a general framework for selecting patient-based outcomes in clinical trials, and apply this framework to the selection of cognitive outcomes. Using the HD-Cognitive Assessment Battery (HD-CAB), a new cognitive battery designed for clinical trials, we illustrate the evaluation of cognitive outcomes in terms of their responsivity, reliability, validity, appropriateness, precision, interpretability, feasibility, and acceptability. Finally, we articulate a pathway for continued development of cognitive tools that would pave the way for finding treatments that ameliorate cognitive decline in HD.

KW - appropriateness

KW - cognitive impairment

KW - endpoint models

KW - HD-CAB

KW - interpretability

KW - precision

KW - psychometrics

KW - reliability

KW - responsivity

KW - validity

UR - http://www.scopus.com/inward/record.url?scp=85037047748&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801893-4.00019-5

DO - 10.1016/B978-0-12-801893-4.00019-5

M3 - Chapter (Book)

VL - 144

T3 - Handbook of Clinical Neurology

SP - 227

EP - 244

BT - Handbook of Clinical Neurology

A2 - Feigin, Andrew S.

A2 - Anderson, Karen E.

PB - Elsevier

CY - Netherlands

ER -

Stout JC, Andrews SC, Glikmann-Johnston Y. Cognitive assessment in Huntington disease clinical drug trials. In Feigin AS, Anderson KE, editors, Handbook of Clinical Neurology. Vol. 144. Netherlands: Elsevier. 2017. p. 227-244. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-12-801893-4.00019-5